Literature DB >> 15977247

Evolution over a 10 year period of the epidemiological profile of 1,726 newly diagnosed HCV patients in Belgium.

Christiane Gérard1, Jean Delwaide, Dolores Vaira, Boris Bastens, Benoît Servais, Etienne Wain, Christian Bataille, Guy Daenen, Jacques Belaïche.   

Abstract

In order to evaluate the future burden of hepatitis C, there is a need to quantify the evolution with time of some crucial parameters such as disease frequency and age, modes of infection and infecting genotypes of patients presenting for the first time at consultation. The yearly evolution of these parameters was analyzed retrospectively in a cohort of 1,726 patients living in Belgium, who were diagnosed as hepatitis C virus (HCV) carriers by polymerase chain reaction (PCR) between 1992 and 2002. The epidemiological profile of HCV patients showed significant changes during this period. The number of new patients increased with time. The proportion of patients under 50 increased linearly at a rate of 3% per year. The rate of newly presenting patients infected by transfusion before 1990 decreased, but only by 2.7% per year. The proportion of intravenous (IV) drug users increased by 2.5% per year. Patients presenting "undefined" risk factors increased by 2.1% per year. Nosocomial acquisition of HCV infection exhibited a disturbing relative stability in time whereas dialysis tended to disappear as a cause of infection. There was a significant linear annual decrease of 2.3% in the frequency of genotype 1b, which was counterbalanced by a significant increase of 0.7% for genotype 1a and 1.1% for genotype 4. Genotypes 2 and 3 did not vary significantly with time. Such figures are useful for evaluating the epidemiological changes of C virus infection and for anticipating the future economical cost of hepatitis C treatment in the next few years. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15977247     DOI: 10.1002/jmv.20390

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia.

Authors:  April M Young; Richard A Crosby; Carrie B Oser; Carl G Leukefeld; Dustin B Stephens; Jennifer R Havens
Journal:  J Med Virol       Date:  2012-09       Impact factor: 2.327

Review 2.  Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens.

Authors:  Umberto Vespasiani-Gentilucci; Giovanni Galati; Paolo Gallo; Antonio De Vincentis; Elisabetta Riva; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

3.  HCV genotype distribution in Flanders and Brussels (Belgium): unravelling the spread of an uncommon HCV genotype 5a cluster.

Authors:  J Verbeeck; L Kwanten; F D'Heygere; A Beguin; S Michiels; I Desombere; G Leroux-Roels; P Lemey; F Nevens; M Van Ranst
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-10       Impact factor: 3.267

4.  Investigating the origin and spread of hepatitis C virus genotype 5a.

Authors:  Jannick Verbeeck; Piet Maes; Philippe Lemey; Oliver G Pybus; Elke Wollants; Ernie Song; Frederik Nevens; Johan Fevery; Wayne Delport; Schalk Van der Merwe; Marc Van Ranst
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 5.  Epidemiology of hepatitis C virus infection.

Authors:  Miriam J Alter
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

6.  Colonial history and contemporary transmission shape the genetic diversity of hepatitis C virus genotype 2 in Amsterdam.

Authors:  Peter V Markov; Thijs J van de Laar; Xiomara V Thomas; Sem J Aronson; Christine J Weegink; Guido E van den Berk; Maria Prins; Oliver G Pybus; Janke Schinkel
Journal:  J Virol       Date:  2012-05-09       Impact factor: 5.103

7.  Distribution of HCV genotypes in Belgium from 2008 to 2015.

Authors:  Lobna Bouacida; Vanessa Suin; Veronik Hutse; Michaël Boudewijns; Reinoud Cartuyvels; Laurent Debaisieux; Emmanuel De Laere; Marie Hallin; Nicolas Hougardy; Katrien Lagrou; Els Oris; Elizaveta Padalko; Marijke Reynders; Gatien Roussel; Jean-Marc Senterre; Michel Stalpaert; Dominique Ursi; Carl Vael; Dolores Vaira; Jos Van Acker; Walter Verstrepen; Steven Van Gucht; Benoit Kabamba; Sophie Quoilin; Gaëtan Muyldermans
Journal:  PLoS One       Date:  2018-12-05       Impact factor: 3.240

8.  Never injected, but hepatitis C virus-infected: a study among self-declared never-injecting drug users from the Amsterdam Cohort Studies.

Authors:  C H S B van den Berg; T J W van de Laar; A Kok; F R Zuure; R A Coutinho; M Prins
Journal:  J Viral Hepat       Date:  2009-02-23       Impact factor: 3.728

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.